[Pramipexole therapy of restless legs syndrome].
Ideggyogy Sz. 2007 Jan 20; 60(1-2):15-22.IS

Abstract

The restless legs syndrome is a disorder belonging to the family of movement disorders during sleep, often remains unrecognized, although it is the second most common cause of chronic sleep deficiency and daytime sleepiness. In accordance with international guidelines, pharmacotherapy of this disorder should begin with a dopamine agonist. Owing to their efficacy and favorable safety profile, newly introduced, selective dopamine agonists have become extensively used for this purpose. This study evaluated the efficacy of one of the products in this group, pramipexole. Fifty-one patients suffering from idiopathic restless legs syndrome underwent monotherapy with pramipexole in daily doses of 0.25 to 1.0 mg. Therapeutic efficacy was evaluated using three tools, i.e. follow-up questionnaires, actigraphy, and Forced Immobilisation Test. An excellent therapeutic effect was seen in more than 80 per cent of the study population. As shown by findings of the follow-up questionnaires, pramipexole resulted in substantial improvements of both daytime and nighttime symptoms of RLS. Actigraphy monitoring demonstrated a statistically significant increase in the ratio of time spent without limb movement to the time spent in bed; furthermore, the result of the Forced Immobilisation Test also improved. It seems fair to conclude from the findings of this study that pramipexole monotherapy is an effective treatment in restless legs syndrome.

Authors+Show Affiliations

Vida Z

vida@hypnos.axelero.net

Szakács Z

No affiliation info available

MeSH

BenzothiazolesDopamine AgonistsDrug Administration ScheduleFollow-Up StudiesHumansImmobilizationPolysomnographyPramipexoleRestless Legs SyndromeSeverity of Illness IndexSleepSurveys and QuestionnairesTreatment Outcome

Pub Type(s)

Clinical Trial

Journal Article

Language

hun

PubMed ID

17432089

Citation

Vida, Zsuzsanna, and Zoltán Szakács. "[Pramipexole Therapy of Restless Legs Syndrome]." Ideggyogyaszati Szemle, vol. 60, no. 1-2, 2007, pp. 15-22.

Vida Z, Szakács Z. [Pramipexole therapy of restless legs syndrome]. Ideggyogy Sz. 2007;60(1-2):15-22.

Vida, Z., & Szakács, Z. (2007). [Pramipexole therapy of restless legs syndrome]. Ideggyogyaszati Szemle, 60(1-2), 15-22.

Vida Z, Szakács Z. [Pramipexole Therapy of Restless Legs Syndrome]. Ideggyogy Sz. 2007 Jan 20;60(1-2):15-22. PubMed PMID: 17432089.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - [Pramipexole therapy of restless legs syndrome]. AU - Vida,Zsuzsanna, AU - Szakács,Zoltán, PY - 2007/4/17/pubmed PY - 2007/6/15/medline PY - 2007/4/17/entrez SP - 15 EP - 22 JF - Ideggyogyaszati szemle JO - Ideggyogy Sz VL - 60 IS - 1-2 N2 - The restless legs syndrome is a disorder belonging to the family of movement disorders during sleep, often remains unrecognized, although it is the second most common cause of chronic sleep deficiency and daytime sleepiness. In accordance with international guidelines, pharmacotherapy of this disorder should begin with a dopamine agonist. Owing to their efficacy and favorable safety profile, newly introduced, selective dopamine agonists have become extensively used for this purpose. This study evaluated the efficacy of one of the products in this group, pramipexole. Fifty-one patients suffering from idiopathic restless legs syndrome underwent monotherapy with pramipexole in daily doses of 0.25 to 1.0 mg. Therapeutic efficacy was evaluated using three tools, i.e. follow-up questionnaires, actigraphy, and Forced Immobilisation Test. An excellent therapeutic effect was seen in more than 80 per cent of the study population. As shown by findings of the follow-up questionnaires, pramipexole resulted in substantial improvements of both daytime and nighttime symptoms of RLS. Actigraphy monitoring demonstrated a statistically significant increase in the ratio of time spent without limb movement to the time spent in bed; furthermore, the result of the Forced Immobilisation Test also improved. It seems fair to conclude from the findings of this study that pramipexole monotherapy is an effective treatment in restless legs syndrome. SN - 0019-1442 UR - https://www.unboundmedicine.com/medline/citation/17432089/Current_status_of_antifungal_susceptibility_testing_methods_ L2 - http://www.diseaseinfosearch.org/result/6228 DB - PRIME DP - Unbound Medicine ER -

Tags

[Pramipexole therapy of restless legs syndrome].Ideggyogy Sz. 2007 Jan 20; 60(1-2):15-22.IS